Table 1. Surgical cases, perioperative hemostatic management, and outcomes.
|
Case No. |
Patient No. |
Procedure |
Preoperative aPTT (21.0-34.5) (sec) |
Severity |
Clotting factor & dose |
TXA |
Anesthesia |
LOS (days) |
Outcome |
|---|---|---|---|---|---|---|---|---|---|
|
1 |
Patient 1 |
Surgical extraction #18, #48 |
28.0 |
Moderate |
Adynovate 4,000 U preop→ 2,000 U qd×1d; 2,000 U q8h×2d |
IV 500 mg q8h×3d (admission)→ PO 500 mg tid×5d at discharge |
Local |
4 |
Success |
|
2 |
Patient 1 |
Surgical extraction #28, #38 |
27.6 |
Moderate |
Adynovate 4,500 U preop→ 2,000 U qd×1d; 2,000 U q8h×2d; 2,000 U q12h×1d |
IV 500 mg q8h×4d (admission)→ PO 500 mg tid×5d at discharge |
Local |
5 |
Success |
|
3 |
Patient 2 |
Scaling; Simple extraction #45 |
26.6 |
Mild |
GreenGene F 3,400 U preop→1,700 U qd×1d; 1,700 U q12h×3d |
PO only: Transamin 500 mg (2 cap) tid×10d, started morning of procedure |
Local |
Outpt |
Success |
|
4 |
Patient 2 |
Implants #44,46,47 + GBR |
27.2 |
Mild |
GreenGene F 3,500 U preop→1,750 U qd×1d; 1,750 U q12h×3d |
PO only: Transamin 500 mg (2 cap) tid×10d, started night before procedure |
Local |
Outpt |
Success |
|
5 |
Patient 3 |
Surgical extraction #28, #38 |
31.0 |
Mild |
Rixubis 10,000 U preop→5,000 or 6,000 U q8h×3d; 5,000 U q12h×2d; 5,000 U qd×2d |
IV 500 mg q8h×8d (admission)→ PO 500 mg tid×3d at discharge |
Local |
9 |
Delayed bleeding→readmission |
|
6 |
Patient 3 |
Surgical extraction #18, #48 |
29.6 |
Mild |
Rixubis 10,000 U preop→5,000 or 6,000 U q8h×2d; 5,000 U q12h×1d; 5,000 U qd×1d |
IV 500 mg q8h×5d (admission)→ PO 500 mg tid×7d at discharge |
Local |
6 |
Success |
|
7 |
Patient 4 |
Surgical extraction #28, #38 |
25.8 |
Unknown |
Adynovate 3,000 U preop→1,500 U qd×1d; 1,500 U q8h×3d |
IV 500 mg q8h×4d (admission)→ PO 250 mg tid×7d at discharge |
Local |
5 |
Success |
|
8 |
Patient 4 |
Surgical extraction #18, #48 |
27.2 |
Unknown |
Adynovate 3,000 U preop→1,500 U qd×1d; 1,500 U q8h×3d |
IV 500 mg q8h×4d (admission)→ PO 500 mg tid×5d at discharge |
Local |
5 |
Success |
|
9 |
Patient 5 |
Surgical extraction #18, #48 |
24.6 |
Severe |
Adynovate 3,000 U preop→1,500 U qd×1d; 1,500 U q8h×2d; 1,500 U qd×1d |
IV 500 mg q8h×4d (admission)→ PO 500 mg tid×7d at discharge |
Local |
5 |
Success |
|
10 |
Patient 5 |
Surgical extraction #28, #38 |
26.1 |
Severe |
Adynovate 3,000 U preop→1,500 U qd×1d; 1,500 U q8h×2d; 1,500 U qd×1d |
IV 500 mg q8h×4d (admission)→ PO 500 mg tid×7d at discharge |
Local |
5 |
Success |
|
11 |
Patient 6 |
Surgical extraction #18, #48 |
34.4 |
Severe |
Afstyla 3,300 U preop→1,500 U q12h×1d; 1,500 U q8h×3d; 1,500 U q12h×2d; 1,500 U qd×2d |
IV 500 mg q8h×8d (admission)→ PO 500 mg tid×2d at discharge |
Local |
9 |
Odontogenic infection→antibiotics |
|
12 |
Patient 7 |
Simple extraction #63 |
Not performed |
Mild |
Advate 2,000 U preop; 2,000 U qd×1d (outpatient) |
Outpatient, PO only: Transamin 250 mg qd×1d preop + 250 mg tid×7d postop |
Local |
Outpt |
Success |
|
13 |
Patient 7 |
Simple extraction #52, #53, #54 |
Not performed |
Mild |
Advate 2,000 U preop; 2,000 U qd×2d (outpatient) |
Outpatient, PO only: Transamin 250 mg qd×1d preop + 250 mg tid×7d postop |
Local |
Outpt |
Success |
|
14 |
Patient 8 |
Surgical extraction #48 |
26.2 |
Severe |
Advate 4,000 U preop→1,500 U q8h×3d, taper×2d |
IV 500 mg q8h×4d (admission)→ PO 500 mg tid×7d at discharge |
Local |
5 |
Success |
|
15 |
Patient 8 |
Surgical extraction #18, #28, #38 |
26.1 |
Severe |
Advate 4,000 U preop→1,500 U q8h×3d, taper×2d |
IV 500 mg q8h×4d (admission)→ PO 500 mg tid×7d at discharge |
Local |
5 |
Success |
|
16 |
Patient 9 |
Simple extraction #23; root planing #22, #24 |
Not performed |
Moderate |
Advate 4,000 U preop; 4,000 U qd×1d (outpatient) |
Outpatient, PO only: Transamin 500 mg (2 cap) tid×7d, started morning of procedure |
Local |
Outpt |
Success |
|
17 |
Patient 10 |
Scaling + curettage; simple extraction #31, #33 |
Not performed |
Severe |
FEIBA 6,680 U preop→6,680 U qd×1d; additional dose for oozing |
IV 500 mg q8h×4d (admission)→ PO 500 mg tid×7d at discharge |
Local |
5 |
Minor oozing→additional FEIBA |
|
18 |
Patient 11 |
Surgical extraction #28, #38 |
26.7 |
Severe |
BeneFIX 11,000 U preop→5,000 U qd×1d; 5,000 U q12h×2d |
IV 500 mg q8h×3d (admission)→ PO 500 mg tid×7d at discharge |
Local |
4 |
Success |
|
19 |
Patient 11 |
Surgical extraction #48 |
27.3 |
Severe |
BeneFIX 11,000 U preop→5,000 U qd×1d; 5,000 U q12h×2d |
IV 500 mg q8h×3d (admission)→ PO 500 mg tid×7d at discharge |
Local |
4 |
Success |
|
20 |
Patient 12 |
Cyst enucleation + apicoectomy #22 |
27.3 |
Severe |
Green Mono 4,000 U preop→2,000 U q8h×3d |
IV 500 mg q8h×4d (admission) |
Local |
5 |
Success |
|
21 |
Patient 13 |
Surgical extraction #18, #28, #38, #48 (GA) |
26.1 |
Severe |
Advate 5,000 U preop→1,750+3,000 U qd postop; 1,750+3,000 U q8h×2d; 1,750+2000 U q8h×1d, 1,750 or 2,000 U q8h×1d, 1,750 U qd×1d |
IV 500 mg q8h×6d (admission, under GA)→PO 500 mg tid×7d at discharge |
General |
7 |
Success |
(GBR: guided bone regeneration, TXA: tranexamic acid, q: every, h: hours, d: days, QD: once daily, preop: immediately before surgery, U: international units, LOS: length of stay, IV: intravenous, PO: per oral, Outpt: outpatient [no inpatient admission])
All IV TXA was tranexamic acid injection (Shinpoong) 500 mg/5 mL given by slow intravenous push; all PO TXA was Transamin capsule 250 mg.